NFE2L2 and cancer: Further, NRF2 and KEAP1 mutations are common in many cancers and lead to impaired NRF2 degradation and constitutive NRF2 accumulation (Ohta et al., 2008; Shibata et al., 2008), thereby promoting glutathione (GSH) synthesis, detoxification of reactive oxygen species (ROS) and proliferation.